KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ:KALV
KALV Stock Chart & Stats
$20.13
-$0.39(-4.51%)
At close: 4:00 PM EST
$20.13
-$0.39(-4.51%)
Day’s Range― - ―
52-Week Range$9.24 - $20.59
Previous CloseN/A
Volume49.40K
Average Volume (3M)1.00M
Market Cap
$1.03B
Enterprise Value$1.09B
Total Cash (Recent Filing)$300.21M
Total Debt (Recent Filing)$284.21M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Jul 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding51,222,490
10 Day Avg. Volume1,269,288
30 Day Avg. Volume1,000,080
Financial Highlights & Ratios
PEG Ratio-0.51
Price to Book (P/B)7.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.46
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue14.47
Enterprise Value/Gross Profit21.06
Enterprise Value/Ebitda-5.30
Forecast
1Y Price Target
$35.88Price Target Upside78.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.73
Revenue Forecast (FY)$205.06M
Bulls Say, Bears Say
Bulls Say
Commercial Expansion And Cash RunwayEarly international uptake alongside a sufficient cash runway supports potential revenue upside outside the U.S. while reducing near‑term financing risk during continued commercialization.
Payer And Guideline SupportInclusion in international pediatric guidelines combined with favorable payer commentary suggests expanding medical endorsement and continued patient access to the oral therapy.
Refill-driven Launch MomentumStrong prescription refill volumes for Ekterly indicate repeated patient use and point to sustainable revenue growth as treatment frequency increases.
Bears Say
International Pricing PressureSignificant discounting of ex‑US prices could constrain the contribution of international markets and cap overall global revenue expansion.
Limited Visibility On Inventory And Payer MetricsInsufficient disclosure on specialty pharmacy inventory and payer dynamics limits clarity on organic demand versus timing effects, complicating near‑term sales forecasts.
Refill Durability Risk As Patient Mix BroadensRefill intensity may decline as the treated population expands beyond high‑burden patients, creating uncertainty around sustained per‑patient usage and future revenue.
KalVista Pharmaceuticals News
KALV FAQ
What was KalVista Pharmaceuticals, Inc.’s price range in the past 12 months?
KalVista Pharmaceuticals, Inc. lowest stock price was $9.23 and its highest was $20.59 in the past 12 months.
What is KalVista Pharmaceuticals, Inc.’s market cap?
KalVista Pharmaceuticals, Inc.’s market cap is $1.03B.
When is KalVista Pharmaceuticals, Inc.’s upcoming earnings report date?
KalVista Pharmaceuticals, Inc.’s upcoming earnings report date is Jul 02, 2026 which is in 92 days.
How were KalVista Pharmaceuticals, Inc.’s earnings last quarter?
KalVista Pharmaceuticals, Inc. released its earnings results on Mar 17, 2026. The company reported -$0.92 earnings per share for the quarter, missing the consensus estimate of -$0.672 by -$0.248.
Is KalVista Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts KalVista Pharmaceuticals, Inc.’s price is currently Undervalued.
Does KalVista Pharmaceuticals, Inc. pay dividends?
KalVista Pharmaceuticals, Inc. does not currently pay dividends.
What is KalVista Pharmaceuticals, Inc.’s EPS estimate?
KalVista Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KalVista Pharmaceuticals, Inc. have?
KalVista Pharmaceuticals, Inc. has 51,222,490 shares outstanding.
What happened to KalVista Pharmaceuticals, Inc.’s price movement after its last earnings report?
KalVista Pharmaceuticals, Inc. reported an EPS of -$0.92 in its last earnings report, missing expectations of -$0.672. Following the earnings report the stock price went down -1.546%.
Which hedge fund is a major shareholder of KalVista Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in KALV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
KalVista Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.88 (78.24% Upside)
$35.88 (78.24% Upside)
Blogger Sentiment
Neutral
KALV Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 428.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.89%
12-Months-Change
Fundamentals
Return on Equity
-444.41%
Trailing 12-Months
Asset Growth
33.74%
Trailing 12-Months
Company Description
KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
KALV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive sentiment, highlighting significant achievements such as the FDA approval and successful early launch of EKTERLY, strong patient and prescriber engagement, and positive regulatory progress in Europe. However, challenges remain with high operating expenses and potential reimbursement hurdles with certain insurers.View all KALV earnings summariesKALV Stock 12 Month Forecast
Average Price Target
$35.88
▲(78.24% Upside)
Technical Analysis
Savara
―
Arvinas Holding Company
―
Gossamer Bio
―
Compass Therapeutics
―
Bicara Therapeutics Inc.
―
Ownership Overview
Currently, No data available
---